Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide versus cyclosporin + methotrexate for GVHD prophylaxis after matched sibling allogeneic transplant
ACTRN12618000505202Phase 3Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of cyclophosphamide in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), sponsored by Australasian Leukaemia & Lymphoma Group. Started Apr 2019; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12618000505202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000505202.